US FDA approves GE HealthCare’s diagnostic drug for the treatment of heart disease
The US Food and Drug Administration has approved a GE HealthCare diagnostic drug for use in the detection of coronary heart disease. Flyrcado, a radioactive diagnostic drug for positron emission tomography (PET) and myocardial perfusion imaging (MPI), will go on sale in some US markets in early 2025, after which it will be expanded.
BELIEBTE BEITRÄGE
Earthquakes and emissions undermine the idea of carbon storage in Texas
Dezember 17, 2024
Rescuers search for cyclone survivors in devastated Mayotte
Dezember 17, 2024
“Gilmore Girls” airs for a second season on Hulu
Dezember 17, 2024
LIVEÜBERTRAGUNG